SBIR-STTR Award

Composite Supports For Rapid Polynucleotide Synthesis
Award last edited on: 3/5/07

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$835,311
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Richard F Hammen

Company Information

ChelaTech Inc (AKA: Chromatochem Inc)

4200 Fox Farm Road
Missoula, MT 59804
   (406) 728-5897
   chelatec@aol.com
   www.chelatech.biz
Location: Single
Congr. District: 00
County: Missoula

Phase I

Contract Number: 1R43GM062711-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2001
Phase I Amount
$99,975
Modern DNA synthesis methods make use of porous solid phase supports that are used to immobilize the first base in the sequence. This process is inherently inefficient, because solutes and solvent flowing through a column of porous media prefer the path of least resistance. Flow naturally goes around the particles, rather than through the tortuous pathway of the pores where the synthetic DNA is being made. This causes slow reaction kinetics and poor use of expensive reagents. A more serious problem is the fact that it is not feasible to synthesize long polynucleotides. The size constraints of the narrow pores make it impossible to prepare long DNA sequences in acceptable yields and purities. This Phase I Research proposes to literally turn this problem inside out, by synthesizing composite materials consisting of nonporous particles with spider webs of functional polymers crossing the interstitial spaces between the particles. The Aim of this Research is to attach nucleosides to the spider webs and synthesize DNA that will be positioned thousands of Angstroms from the surface of the solid support. Prototype products will be developed in Phase I, and tested for their yields of synthetic DNA production. PROPOSED COMMERCIAL APPLICATION: The composite materials developed in this Research will enable the high speed, low cost, production of both short and long DNA sequences. This will have a revolutionary effect in the entire biotechnology and pharmaceutical industries, and will reduce product development time and costs.

Phase II

Contract Number: 2R44RR014158-02A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2001
(last award dollars: 2002)
Phase II Amount
$735,336

Research and drug development in the pharmaceutical industry rely heavily upon separation science, particularly in this era of High Throughput genomic and proteomic analyses. Chromatographic methods used today separate proteins from other molecules by interactions with a solid porous support Solutes and solvent flowing through a chromatographic column of porous media prefer the path of least resistance and flow around the particles, rather than the tortuous pathway through the narrow pores where the functional chemistry is located. This leads to slow adsorption-desorption kinetics, band spreading, and loss of resolution. This Phase I Research was successful in literally turning this problem inside out, by synthesizing composite materials consisting of nonporous particles with "spider webs" of functional ligands crossing the interstitial spaces between the particles. The Specific Aims of this Research are to synthesize a series of composite chromatography columns with functional groups immobilized by extended tethers that place the functional molecule thousands of Angstroms from the surface of the solid support. Prototype products will be developed for the High Throughput Chromatography of a variety of proteins in both a column format and in a parallel plate format that will perform separations in a few seconds. PROPOSED COMMERCIAL APPLICATION: The composite materials developed in this Research will find commercial use for High Throughput Chromatographic separations and bioassays. Corporate partners will assist ChelaTech in evaluating the performance and the market competitiveness of the prototype products developed in Phase II. The sale and deployment of these products to the pharmaceutical and healthcare research industries will enable cost reductions, enhanced accuracy, and productivity increases in research to cure human disease.